GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Financial Strength

MetaStat (MetaStat) Financial Strength : 0 (As of Feb. 2018)


View and export this data going back to 2008. Start your Free Trial

What is MetaStat Financial Strength?

MetaStat has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

MetaStat did not have earnings to cover the interest expense. As of today, MetaStat's Altman Z-Score is 0.00.


Competitive Comparison of MetaStat's Financial Strength

For the Biotechnology subindustry, MetaStat's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Financial Strength distribution charts can be found below:

* The bar in red indicates where MetaStat's Financial Strength falls into.



MetaStat Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

MetaStat's Interest Expense for the months ended in Feb. 2018 was $-0.03 Mil. Its Operating Income for the months ended in Feb. 2018 was $-0.88 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2018 was $0.00 Mil.

MetaStat's Interest Coverage for the quarter that ended in Feb. 2018 is

MetaStat did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

MetaStat's Debt to Revenue Ratio for the quarter that ended in Feb. 2018 is

Debt to Revenue Ratio=Total Debt (Q: Feb. 2018 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1 + 0) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

MetaStat has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MetaStat  (OTCPK:MTST) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

MetaStat has the Financial Strength Rank of 0.


MetaStat Financial Strength Related Terms

Thank you for viewing the detailed overview of MetaStat's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


MetaStat (MetaStat) Business Description

Traded in Other Exchanges
N/A
Address
27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Executives
Daniel H Schneiderman officer: VP OF FINANCE AND SECRETARY 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings director 11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll director C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor director 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel director T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau director 2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein director OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins 10 percent owner 730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz director 10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines